← Back to screener

Foghorn Therapeutics Inc. FHTX

Rank #1987 · Nasdaq · $0.1B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
37.1
P/E
-1.4
P/B
-1.58
ROE
112.2%
Op. Margin
-454.3%
Debt Ratio
-427%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -1.4x, P/B -1.58x. Ranks in the top 98% of the universe.

Profitability ★★★☆☆
Average

ROE 112.2%. Ranks in the top 49% of the universe.

Safety ★★★★★
Excellent

Debt ratio -427%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 33.8% year over year. Ranks in the top 95% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.1B$-0.1B$-0.0B-11880.0-61
2021$0.0B$-0.1B$-0.1B$-0.1B-15937.4-124
2022$0.0B$-0.1B$-0.1B$0.1B-7637.1289
2023$0.0B$-0.1B$-0.1B$0.1B-609.2418
2024$0.0B$-0.1B$-0.1B$0.0B-315.9324202
2025$0.0B$-0.1B$-0.1B$-0.1B-454.3-427

← See the full screener